McKesson Co. (NYSE:MCK – Get Rating) EVP Nancy Flores sold 3,298 shares of the company’s stock in a transaction on Thursday, April 7th. The shares were sold at an average price of $311.09, for a total value of $1,025,974.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NYSE:MCK opened at $325.84 on Monday. The stock has a 50-day simple moving average of $285.71 and a 200-day simple moving average of $247.16. The stock has a market cap of $48.81 billion, a P/E ratio of 36.65, a P/E/G ratio of 1.21 and a beta of 0.72. McKesson Co. has a 1 year low of $180.41 and a 1 year high of $327.82.
McKesson (NYSE:MCK – Get Rating) last released its quarterly earnings data on Wednesday, February 2nd. The company reported $6.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $5.38 by $0.77. The business had revenue of $68.61 billion during the quarter, compared to analysts’ expectations of $66.63 billion. McKesson had a negative return on equity of 1,931.18% and a net margin of 0.55%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.60 EPS. As a group, research analysts forecast that McKesson Co. will post 23.91 EPS for the current fiscal year.
Several equities analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft lowered McKesson from a “buy” rating to a “hold” rating and upped their price target for the company from $262.00 to $270.00 in a research note on Friday, February 4th. They noted that the move was a valuation call. TheStreet upgraded McKesson from a “d” rating to a “c+” rating in a report on Wednesday, February 2nd. Credit Suisse Group began coverage on McKesson in a report on Friday, April 1st. They issued an “outperform” rating and a $333.00 price objective on the stock. Mizuho boosted their price objective on McKesson from $250.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, February 7th. Finally, UBS Group boosted their price objective on McKesson from $245.00 to $303.00 and gave the company a “buy” rating in a report on Tuesday, February 8th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $285.38.
Large investors have recently added to or reduced their stakes in the company. West Oak Capital LLC acquired a new position in shares of McKesson during the 4th quarter worth about $25,000. Cornerstone Advisory LLC acquired a new stake in shares of McKesson in the 4th quarter valued at about $25,000. Ahrens Investment Partners LLC acquired a new stake in shares of McKesson in the 4th quarter valued at about $26,000. Amplius Wealth Advisors LLC acquired a new stake in shares of McKesson in the 4th quarter valued at about $25,000. Finally, Mascoma Wealth Management LLC acquired a new stake in shares of McKesson in the 4th quarter valued at about $28,000. 86.01% of the stock is owned by institutional investors and hedge funds.
About McKesson (Get Rating)
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
- Get a free copy of the StockNews.com research report on McKesson (MCK)
- Conagra Stock Has More Room to Grow
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
- The Institutional Insiders Are Buying WD-40 Company
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.